CD276 and cancer: An anti-CD276 monoclonal antibody (mAb) was developed for cancer therapy [43], which, under the name Enoblituzumab, is undergoing phase 1–2 clinical trials [44,45,46], that demonstrate the antitumor activity of the drug and an acceptable safety profile [47,48].